QI LU
LIVE

Serial Number

79076475

Owner

QILU PHARMACEUTICAL CO., LTD

Attorney

Dana Stewart-Mekdara

Filing Date

Nov 26, 2009

Add to watchlist:

No watchlists yet
View on USPTO

QI LU Trademark

Serial Number: 79076475 • Registration: 3946913

QI LU is a trademark filed by QILU PHARMACEUTICAL CO., LTD on November 26, 2009. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

QILU PHARMACEUTICAL CO., LTD (2 trademarks)

No. 317, Xinluo Road
Shandong 250101 , CN

Entity Type: 99

Trademark Details

Filing Date

November 26, 2009

Registration Date

April 19, 2011

Published for Opposition

February 1, 2011

Goods & Services

[ Pharmaceutical preparations, namely, injections, capsules and tablets for use in ophthalmology, oncology, and chemotherapy; pharmaceutical preparations, namely, injections, capsules and tablets for the treatment of disorders of the nervous system, cardio-vascular system and respiratory system; pharmaceutical preparations, namely, injections, capsules and tablets for the treatment of diseases and disorders in the gastrointestinal system, endocrine system and psychiatric system; pharmaceutical preparations, namely, injections, capsules and tablets for the treatment of inflammation; ] biomedical medicines for use in ophthalmology, oncology and chemotherapy; [ biomedical medicines for the treatment of disorders of the nervous system, cardio-vascular system and respiratory system; biomedical medicines for the treatment of diseases and disorders in the gastrointestinal system, endocrine system and psychiatric system; biomedical medicines for the treatment of inflammation; ] medicines for humans for use in ophthalmology, oncology and chemotherapy; [ medicines for humans for the treatment of disorders of the nervous system, cardio-vascular system and respiratory system; medicines for humans for the treatment of gastrointestinal system, endocrine system and psychiatric system related diseases and disorders; medicines for humans for the treatment of inflammation; ] drugs for medical purposes for use in ophthalmology, oncology and chemotherapy [ ; drugs for medical purposes for the treatment of disorders of the nervous system, cardio-vascular system and respiratory system; drugs for medical purposes for the treatment of gastrointestinal system, endocrine system and psychiatric system related diseases and disorders; drugs for medical purposes, namely, the treatment of inflammation ]

Filing History

PARTIAL INVALIDATION PROCESSED BY THE IB
Nov 6, 2022 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 26, 2022 INPS
INVALIDATION PROCESSED
Sep 26, 2022 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 30, 2022 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Dec 30, 2021 NA71
REGISTERED-SEC.71 ACCEPTED
Dec 30, 2021 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 4, 2021 APRE
TEAS SECTION 71 RECEIVED
Jun 1, 2021 ES71
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Dec 10, 2020 CORR
CORRECTION TRANSACTION RECEIVED FROM IB
Oct 16, 2020 CRCV
CHANGE OF NAME/ADDRESS REC'D FROM IB
Aug 28, 2020 ADCH
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Apr 19, 2020 REM4
INTERNATIONAL REGISTRATION RENEWED
Dec 12, 2019 RNWL
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Mar 25, 2017 NA71
REGISTERED-SEC.71 ACCEPTED
Mar 25, 2017 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 24, 2017 APRE
TEAS SECTION 71 RECEIVED
Oct 11, 2016 ES71
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 11, 2016 TCCA
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 24, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 9, 2011 FICS
FINAL DISPOSITION PROCESSED
Sep 9, 2011 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 19, 2011 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 19, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 1, 2011 NPUB
PUBLISHED FOR OPPOSITION
Feb 1, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 30, 2010 PREV
ASSIGNED TO LIE
Dec 29, 2010 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 6, 2010 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 16, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 16, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 16, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 3, 2010 GNRN
NON-FINAL ACTION E-MAILED
Sep 3, 2010 GNRT
NON-FINAL ACTION WRITTEN
Sep 3, 2010 CNRT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 20, 2010 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 18, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 16, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 16, 2010 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 16, 2010 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 16, 2010 TCCA
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Apr 26, 2010 CORR
CORRECTION TRANSACTION RECEIVED FROM IB
Apr 15, 2010 CRCV
REFUSAL PROCESSED BY IB
Apr 9, 2010 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 12, 2010 RFCS
REFUSAL PROCESSED BY MPU
Mar 11, 2010 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 11, 2010 RFCR
NON-FINAL ACTION WRITTEN
Mar 10, 2010 CNRT
ASSIGNED TO EXAMINER
Mar 3, 2010 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 2, 2010 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 29, 2009 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 24, 2009 REPR